Enzymatic DNA Synthesis Market Size, Share & Industry Analysis, By Offering (Products {Instruments and Consumables [Reagent & Kits, Molecular Probes, and Others]}, and Services {Fragment XP Synthesis, Gene Shuttle Vector, Enzymatic DNA Assembly & Cloning Services, and Others}), By Technology (Template-Free Therapy, Vaccine Manufacturing, Research, and Others), By End User (Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, CDMOS, CROS, and Others), and Regional Forecast, 2026-2034

The global enzymatic DNA synthesis market size was valued at USD 280.2 million and is projected to reach USD 1,670.1 million by 2032, exhibiting a CAGR of 24.5% during the forecast period.

The global market is experiencing significant growth due to the numerous advantages of enzymatic DNA synthesis over other alternative methods. The enzymatic DNA synthesis process enables the generation of longer, purer, and more accurate DNA strands but reduces turnaround time. These benefits accelerate the development of vaccines and nucleic acid therapeutics, propelling the demand. Various established players are focusing on strategic activities such as collaborations to expand their enzymatic DNA synthesis capabilities. Such factors are expected to bolster the growth of the global enzymatic DNA synthesis market.

• For instance, in June 2024, GSK plc. acquired Elsie Biotechnologies for up to USD 50.0 million. This acquisition integrated Elsie’s oligonucleotide discovery, synthesis, and delivery technologies to enhance GSK’s platform R&D capabilities.

Furthermore, strategic activities such as research and development, collaboration, mergers, and acquisitions of key companies are anticipated to drive the market growth over the upcoming years.

Enzymatic DNA Synthesis Market Driver

Rising Demand for Synthetic Biology and Gene Editing Applications to Drive the Market Growth

The surging demand for synthetic biology and gene editing applications is a key driver of the enzymatic DNA synthesis market. Synthetic biology relies heavily on rapid and accurate DNA synthesis for designing novel metabolic pathways, critical for advanced gene constructs. Enzymatic platforms offer faster turnaround and in-lab synthesis capabilities, supporting research and innovation.

Furthermore, the surge in synthetic biology and gene editing activities, as well as strategic collaborations and partnerships among key companies, continues to fuel the global growth in the adoption of enzymatic DNA synthesis technologies.

• For instance, in March 2025, Syngoi Technologies collaborated with Ribbon Bio GmbH to advance gene therapeutics through the development and manufacturing of clinically and commercially ready synthetic DNA at the gram scale.

Download Free sample to learn more about this report.

In September 2025, ACS publication published an article titled ‘Enzymatic Strategies for Next-Generation DNA Synthesis: Boosting Efficiency and Overcoming Secondary Structures’ that reported a coupling efficiency of 97.7% for enzymatic DNA synthesis.

Enzymatic DNA Synthesis Market Restraint

Stringent Regulatory Framework and Operational Challenges to Hamper the Market Growth

The genetic materials used in enzymatic DNA synthesis must comply with rigorous biosafety, biosecurity, and quality assurance standards, such as the FDA’s Good Manufacturing Practice (GMP) and the OECD’s bioengineering regulations. The process involves multi-step operational protocols, including enzymatic reaction optimization, quality control sequencing, and assembly verification, which increase time and cost burdens. These factors can hamper the market growth.

• For instance, in April 2024, the NIH published an article titled ‘Preparing and Evaluating the Stability of Therapeutically Relevant Oligonucleotide Duplexes’ that urged the standardization of stability of oligonucleotides for reference to researchers, enabling them to compare the impact of various modifications on oligo stability and assess degradation kinetics effectively.

Enzymatic DNA Synthesis Market Opportunity

Rising Investment Opportunities to Offer Lucrative Growth Opportunities

The higher efficiency and sustainability of enzymatic DNA synthesis that complies with industry standards are resulting in a rising demand. To cater to this increasing demand, many key companies are investing in expanding their manufacturing capabilities. These increasing investment opportunities are accelerating enzyme engineering, the launch of benchtop instruments, and the global manufacturing of gene therapies, offering lucrative growth opportunities for the market.

• For instance, in October 2025, Ansa Biotechnologies raised USD 45.2 million and secured an additional USD 9.2 million in commitments for its Series B financing, aiming to expand its DNA synthesis technology. Such rising spending on the development of enzymatic DNA synthesis is expected to drive market growth.

Segmentation

Key Insights

The report covers the following key insights:

• Technological Advancements in Enzymatic DNA Synthesis
• Key Industry Development- Mergers, Acquisitions, Partnerships, and Others)
• New Products/Services Launches, By Key Players
• Key Startups, by Key Countries/Regions
• Regulatory Scenario, By Key Countries/ Regions

Analysis by Offering

Based on offering, the global enzymatic DNA synthesis market is segmented into products and services.

Among these, the product segment is expected to hold a substantial market share. The segment is expected to dominate the market due to the increasing adoption of enzymatic DNA synthesis instruments, reagents, and kits for in-house DNA manufacturing. Numerous benchtop DNA printers and platforms have enabled decentralized, rapid DNA synthesis directly within research facilities. Additionally, the rising focus on automation and sustainability in DNA manufacturing requires investment in hardware and consumable kits. Additionally, collaborations among key operational entities are expected to boost the segment’s growth.

• For instance, in November 2021, DNA Script, a leader in benchtop enzymatic DNA synthesis, received a USD 2.2 million grant award from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) to support the ongoing development of next generation printers to enzymatically print synthetic DNA and RNA as a follow-on to their recently launched SYNTAX System.

Analysis by Technology

The market, based on technology, is categorized into template-free enzymatic assembly, chip-based synthesis, TdT-dNTP conjugates, and others.

The template-free enzymatic assembly segment accounted for a leading market share due to its ability to synthesize DNA without relying on pre-existing templates. It enables the generation of longer, purer, and more accurate DNA constructs compared to traditional chemical synthesis methods. Key companies have commercialized template-free enzymatic platforms that can rapidly and sustainably produce gene-length DNA. The growing preference for this approach solidified its leading market position.

• For instance, in April 2022, Codexis, Inc. partnered with Molecular Assemblies, Inc., to deliver differentiated solutions for the enzymatic synthesis of DNA. The company's fully enzymatic synthesis technology employed a template-free DNA polymerase, terminal deoxynucleotidyl transferase (TdT). These factors are expected to drive the segmental growth.

Analysis by Application

By application, the market is divided into synthetic biology, cell & gene therapy, vaccine manufacturing, research, and others.

The synthetic biology segment holds the dominant share of the enzymatic DNA synthesis market due to its extensive dependence on rapid, high-fidelity DNA construction for designing and assembling genetic circuits, engineered organisms, and metabolic pathways. Short turnaround times for enzymatic DNA synthesis technologies result in more efficient synthetic biology workflows. The ability to synthesize genes on demand reduces reliance on traditional outsourcing, accelerates innovation, and enhances control over data security for biotech and research institutions.

Moreover, new product launches are expected to drive the segmental growth in the enzymatic DNA synthesis market.

• For instance, in July 2024, Ansa Biotechnologies launched its Ansa Clonal DNA and Ansa DNA Fragments products. The development enabled researchers with complex synthetic DNA sequences that were either previously impossible to produce or constrained by significant quality shortcomings and progress-limiting turnaround times. Such wide application of synthetic biology is expected to drive the segment’s growth.

Analysis by End User

The market is fragmented into pharmaceutical and biotechnology companies, research and academic institutes, CDMOS, CROS, and others in terms of end user.

The pharmaceutical and biotechnological companies segment is expected to hold a significant share of the global enzymatic DNA synthesis market. They have extensive use of EDS systems in drug discovery, gene therapy, and vaccine development. The faster turnaround time and superior accuracy allow these pharmaceutical and biotechnology firms to accelerate R&D timelines and reduce their dependency on outsourced synthesis.

• For instance, in January 2025, Maravai acquired the enzymatic DNA synthesis assets and Intellectual Property of Molecular Assemblies to strengthen its portfolio in therapeutic-grade nucleic acid manufacturing. The acquisition aimed to integrate enzymatic DNA synthesis with TriLink’s GMP operations to meet the growing demand from biopharmaceutical and gene therapy developers.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market has been studied across North America, Europe, Latin America, the Middle East & Africa, and Asia Pacific.

North America accounted for the largest share of around 43% of the global enzymatic DNA synthesis market in 2024. The high share of the region in the market is attributed to robust infrastructure and strong investments in synthetic biology and gene therapy R&D initiatives. Such factors augment the requirement for enzymatic DNA synthesis, contributing to market growth in the region. Additional factor supporting regional expansion comprises strategic partnerships for innovative product launches.

• For instance, in May 2024, Molecular Assemblies, Inc., a leader in the field of enzymatic DNA synthesis, launched a Partnering Program to license Molecular Assemblies' Fully Enzymatic SynthesisTM (FESTM) technology for on-site synthesis. This technology accelerated the production of long, pure, and accurate.

Europe is expected to maintain a significant market share during the forecast period. The regional growth of enzymatic DNA synthesis is attributed to supportive EU funding for genomics innovation and strategic collaboration among established players to enhance their production capacities and expand product offerings.

• For instance, in October 2025, Ansa Biotechnologies launched 50 50-kilobase (kb) Clonal DNA product. The company’s enzymatic synthesis platform allowed scientists to design and obtain complete, error-free DNA constructs in 25 days or less.

The Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The region's growth can be attributed to the emergence of regional partnerships and manufacturing hubs, as well as increased government investment in genetic research and vaccine development. Such factors are expected to drive growth in the region over the forthcoming years.

• For instance, in November 2021, OriCiro Genomics Inc., launched the OriCiro Cell-Free Switching system. This system enabled the researchers to quickly switch from using living cells to an easy-to-use cell-free, enzymatic amplification system for plasmid DNA amplification.

Key Players covered

The global enzymatic DNA synthesis market is consolidated, with a few major players capturing the majority of the market share.

The report includes the profiles of the following key players.

• Thermo Fisher Scientific Inc. (U.S.)
• Twist Bioscience. (U.S.)
• Ansa Biotechnologies (U.S.)
• DNA Script (France)
• Camena Bioscience (U.K.)
• Evonetix (U.K.)
• Telesis Bio Inc. (U.S.)
• Molecular Assemblies (U.S.)
• Codexis (U.S.)
• Ribbon Bio GmbH (Austria)

Key Industry Developments

• May 2025: Ribbon Bio GmbH launched MiroSynt DNA, an enzymatic assembly designed to meet the growing demand for complex and highly accurate synthetic DNA molecules.
• January 2021: Codex DNA, Inc. collaborated with Pfizer to access and further develop Codex DNA’s novel Enzymatic DNA synthesis technology for its mRNA-based vaccines and other biopharma products.